ClinicalTrials.gg
Sign In

Drug

Tetrachloroethane clinical trials

studies test it
8
open now
6
in phase 3
0
first study started
2022

Keep track of what changes. Save the tetrachloroethane studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Combined with it in one product

Recombinant oncolytic herpes simplex virus type 1 (R130)
5
Oncolytic virus Injection
4
Oncolytic virus
4
Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
3

Studies by the year they started

8 studies that test it; most in 2023 (7)

Studies that test tetrachloroethane, by start year
YearStudies
20221
20237

By phase

A phase 1/2 study counts in both.

Early Phase 1
8

What it is tested for

Each study’s main condition, where its own words name it.

Osteosarcoma
2
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Ovarian Neoplasms
1
Small Cell Lung Carcinoma
1
Uterine Cervical Neoplasms
1

Who runs them

Industry 8 · Other 0

Shanghai Yunying Medical Technology (8)

Often tested with

Tested in the same studies.

Oncolytic HSV-1 R130 (8)

Studies

Open first, then newest update. How each study uses tetrachloroethane is read from its arms, and is right about nine times in ten.

Testing it · 8

Codes

What other systems call tetrachloroethane · ClinicalTrials.gg INT033223

  • MeSH (NLM) C0155301,1,2,2-tetrachloroethaneOne source NLM
  • UNII (FDA) 1L6BI049XVTETRACHLOROETHANEOne source NLM

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.